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Abstract
Background: Impairments in cognitive functions are common in patients suffering from psychiatric disorders, such as
schizophrenia and bipolar disorder. Cognitive traits have been proposed as useful for understanding the biological and genetic
mechanisms implicated in cognitive function in healthy individuals and in the dysfunction observed in psychiatric disorders.
Methods: Sets of genes associated with a range of cognitive functions often impaired in schizophrenia and bipolar disorder
were generated from a genome-wide association study (GWAS) on a sample comprising 670 healthy Norwegian adults who
were phenotyped for a broad battery of cognitive tests. These gene sets were then tested for enrichment of association in
GWASs of schizophrenia and bipolar disorder. The GWAS data was derived from three independent single-centre
schizophrenia samples, three independent single-centre bipolar disorder samples, and the multi-centre schizophrenia and
bipolar disorder samples from the Psychiatric Genomics Consortium.
Results: The strongest enrichments were observed for visuospatial attention and verbal abilities sets in bipolar disorder.
Delayed verbal memory was also enriched in one sample of bipolar disorder. For schizophrenia, the strongest evidence of
enrichment was observed for the sets of genes associated with performance in a colour-word interference test and for sets
associated with memory learning slope.
Conclusions: Our results are consistent with the increasing evidence that cognitive functions share genetic factors with
schizophrenia and bipolar disorder. Our data provides evidence that genetic studies using polygenic and pleiotropic models
can be used to link specific cognitive functions with psychiatric disorders.
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Introduction
Schizophrenia (SCZ) and bipolar disorder (BPD) are devastat-
ing major psychiatric disorders that affect approximately 1% of the
population worldwide in a lifetime perspective [1]. They are
characterized by prominent clinical symptoms such as delusions
and hallucinations for SCZ, or mania and depression in BPD. In
both disorders, impairments in cognitive function are often
observed, which play major roles in the intellectual and social
dysfunction of the patients [2,3]. Although these impairments are
usually stronger in patients, the deficits are also observed in their
unaffected relatives; for instance, deficits across several cognitive
domains such as learning, memory and executive function have
been observed in unaffected relatives of patients with SCZ [4] or
in their unaffected twin siblings [5]. These studies have shown that
a substantial amount of variance in cognitive abilities and
impairments is due to shared genetic effects between the cognitive
abilities and the psychiatric disorders [6]. It has been suggested
that measures of these neurocognitive functions represent under-
lying phenotypes (or intermediate phenotypes) in patients [7].
They also represent quantitative phenotypes in healthy individuals
that may help characterize the behavioral traits, biological
functions and genetic factors underlying major psychiatric
disorders [8,9].
Genetic susceptibility plays a major role in SCZ and BPD but
the identification of genetic factors is obscured by a complex and
polygenic architecture [10,11]. While the population estimates of
heritability are 64% for SCZ and 59% for BPD [12], the genetic
basis or ‘‘heritability’’ that can be explained by common variants
genotyped in current GWASs [13] is up to 30% and 40%,
respectively. However classical p-value threshold-based GWAS
analyses capture only a small number of variants that together
explain less than 3% of this genetic basis [11] even in large
samples. Thus, alternative approaches to GWAS analysis are
needed to capture the so called ‘‘hidden heritability’’, especially
the 30–40% explained by common factors that are not captured
by threshold-based analyses.
Typically in classical GWAS analysis, because of the high
number of genetic variants tested, a conservative p-value threshold
of 561028 is applied, at the cost of losing many variants of small
effect that are truly implicated in the trait being studied. In
contrast, polygenic methods include genetic variants with smaller
effect (i.e. genetic variants that do not pass the threshold) and
evaluate these variants as a group for their effect on a trait. These
methods can be categorized into two main groups, namely
marker-based methods and gene-based methods. Gene-based
methods offer the additional advantage of being more permissive
to allelic heterogeneity, whereby several independent variants at
the same functional locus can have an effect on the same trait, or
across traits if several phenotypes are being compared. Allelic
heterogeneity is well documented in complex traits. For instance,
in a recent re-analysis of GWAS data, Yang et al. [14] showed that
several variants within a locus were associated independently with
height and body mass index. DISC1 [15], DCLK1 [16,17], TCF4
[18,19], NPAS3 [20,21], and CSMD2 [22,23] are examples of
genes for which associations with psychiatric disorders and
cognitive traits have been described but with different markers
in the gene. Even though type I and II errors could explain these
observations, most of the differences observed between samples
and traits are probably explained by allelic heterogeneity
occurring because several functional variants in a gene have an
effect, or because the genetic structure varies between samples, or
because there is imperfect tagging of the causal variation by the
markers typed [24]. Thus methods that account for allelic
heterogeneity, such as gene-based approaches, are better adapted
to compare association across samples and across traits than
single-marker methods.
Since impaired cognitive abilities are core features of SCZ and
BPD, genetic factors implicated in cognitive abilities are likely to
overlap with the genetic variants implicated in disease risk [9,25].
There is now an increased interest in investigating the genetic
overlap between cognitive functions and psychiatric disorders with
polygenic methods. For instance, in a recently published study,
McIntosh et al.[26] show that a polygenic risk of SCZ calculated
from whole-genome variation was associated with lower IQ at age
70 and greater decline in IQ level. In the present study, we used a
gene-based approach to try to identify which cognitive functions,
from a selection of domains that have been reported as impaired in
SCZ and BPD, show the strongest overlap with these disorders at
the gene level. We chose a gene-based method in order to
integrate the effect of allelic heterogeneity, which is not accounted
for in marker-based polygenic studies. We generated sets of genes
associated with nine different cognitive tests in healthy individuals,
then tested these sets for enrichment in GWASs of SCZ and BPD.
Our most significant finding was that sets of genes associated with
visuospatial attention and verbal abilities were the most signifi-
cantly enriched in the BPD samples and the sets of genes
associated with performance in a colour-word interference test and
with the learning slope in a memory task were enriched in SCZ
samples.
Materials and Methods
Description of the Samples
Ethics Statement. The work described here was approved
by the regional ethical committee for medical research (Project ID:
S-03116) for the NCNG sample and the relevant national ethical
committees for the different samples of patients with psychiatric
disorders. Written consent was obtained from all participating
individuals before initiating the study.
The Norwegian Cognitive NeuroGenetics Sample. The
Norwegian Cognitive NeuroGenetics sample (NCNG) consists of
670 healthy Norwegian subjects extensively tested for different
cognitive abilities, which are described in detail in the protocol
paper from Espeseth et al. [27] (see also Table S1 in File S1). The
participants comprise 457 females and 213 males, with a mean age
of 47.6 (range 18–79 years) recruited in Oslo (n = 499) and Bergen
(n = 171). We selected nine cognitive tests that we consider to best
represent each one of the different cognitive domains relevant to
psychiatric disorders as reported in the literature [25,28–34]. We
generated an estimated Intelligence Quotient (cognitive function
‘‘Estimated IQ’’) from the Vocabulary (cognitive domain
‘‘Verbal abilities’’) and Matrix Reasoning (cognitive function
‘‘Matrix reasoning’’) sub-tests from the Wechsler Abbreviated
Scale of Intelligence [35]. From the California Verbal Learning
Test – second edition [36] we used the total number of words
learned across five trials as a measure for learning (cognitive
function ‘‘Learning’’); the delayed free recall score (cognitive
function ‘‘Delayed verbal memory’’); the third condition from
the D-KEFS Colour-Word Interference Test (Stroop3) (cognitive
function ‘‘Colour-word interference’’) [37]; and the valid,
invalid and neutral conditions of the Cued Discrimination Task
(cognitive functions ‘‘Visuospatial attention 1/2/3’’ respec-
tively) [38]. Although the three visuospatial attention traits are
highly correlated at the phenotypic level, they still correspond to
different cognitive processes (for example, the ability to redirect
Genetic Analysis of Cognitive Traits in Psychiatry
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attention when the cue is invalid); thus we chose to test the three
processes independently.
The NCNG sample was genotyped using the Illumina Human
610-Quad BeadChip, retaining 554,225 SNPs after stringent
quality control, performed using the GenABEL package [39].
Duplicated samples or those from closely related individuals –
identity-by-state threshold $0.85 – were excluded. Individual
samples were removed if the heterozygosity values were greater
than two standard deviations (SDs) (z-test two-tailed P= 0.05) from
the sample mean or if they had sex discrepancies. Since we aimed
at a genetically homogenous sample at the population level to
decrease the genetic heterogeneity, the population structure was
assessed by multidimensional scaling (MDS) analysis using 100K
random single nucleotide polymorphisms (SNPs) to exclude
possible non-Norwegian ancestors (24 samples were excluded).
SNPs were filtered and excluded from the analysis if they had a
call rate ,0.95, minor allele frequency (MAF) ,0.01 and Hardy-
Weinberg Equilibrium (HWE) exact test P ,0.001. For further
details about the NCNG sample and genotyping quality control,
see Espeseth et al. [27] and Davies et al. [40].
The neurocognitive traits were analyzed using linear regression,
as implemented in PLINK (http://pngu.mgh.harvard.edu/
purcell/plink/) [41], using sex and age as covariates (except for
estimated IQ which was already corrected for age).
Psychiatric Disorder Samples. Three independent
GWASs for SCZ were tested (Table 1): a combined German-
Dutch GWAS [42], the Danish sub-sample of the Scandinavian
Collaboration on Psychiatric Etiology (SCOPE) [43], and the
Norwegian Thematically Organized Psychosis (TOP) Study SCZ
sample (extended since the original publication [44]). We also
tested the SCZ multi-centre sample from the Psychiatric Genomics
Consortium (PGC) [19]. 20% of the cases and 22% of the controls
from the PGC sample overlap with the other three samples
(Table 1).
Three independent GWASs for bipolar disorder were tested
(Table 1): an extended BPD GWAS from the previously reported
Norwegian TOP Study BPD sample [45], the German BPD
GWAS [46], and the British Wellcome Trust Case Control
Consortium (WTCCC) [47] BPD sample. We also tested the BPD
multi-centre sample from the PGC [48]. 33% of the cases and
49% of the controls in the PGC sample overlap with the other
samples tested (Table 1).
Thus, in this study, the PGC provides merged and extended
samples rather than independent samples. This is potentially a
more efficient and powerful approach for analyzing the data [49]
than testing independent samples.
Gene Scoring and Gene Set Enrichment Analysis
Scoring the Genes. In order to perform gene-based analyses
on the GWASs, the single SNPs were first assigned to genes, by
taking into account the physical position of the SNPs (i.e. within
the boundaries of the genes) and the linkage disequilibrium (LD) of
the genotyped SNPs with any other SNPs within the gene
boundaries, based on the HapMap CEU reference sample [50].
This gene-based binning of SNPs was performed using the
LDsnpR package [51] with the following parameters: the gene
annotation used was the ‘‘Human Ensembl release 54’’ [52], the
gene boundaries were set to 10kb upstream and downstream of the
gene, the LD data used was the ‘‘HapMap Phase II release 27 in
the CEU population’’, and the pairwise LD threshold was set to r2
$0.8.
After the SNPs were binned to genes, a gene-based association
score was generated for each gene by assigning the minimal p-
value from the SNPs in the bin, corrected for the number of
SNPs in the bin with an adjusted Sidak’s score [53], as
implemented in LDsnpR [51,54]. This method for adjusting
the gene-based score for the number of SNPs has been shown
previously to be comparable to permutation-based scores [55].
The gene scores were 2log10 transformed and ranked (see
Figure 1 for details of the overall procedure). All of the GWASs
(NCNG, SCZ and BPD) were subjected to the same gene-
based analytical protocol. The ranked gene lists from the
NCNG GWASs were then used to produce candidate gene sets
for the subsequent enrichment analysis in SCZ and BPD
samples. For each of the nine neurocognitive traits, eleven gene
sets were generated which contained the top 25, 50, 100, 250,
500, 750, 1,000, 1,250, 1,500, 1,750 and 2,000 most strongly
associated genes (i.e. 99 cognitive trait-associated gene sets in
total). Sets of genes of different sizes were selected in order to
represent different significance thresholds, independent of p-
value thresholds which are influenced by the power of
particular individual GWAS and therefore not directly com-
parable across GWASs. By scanning different thresholds, we
aimed to identify the set of top genes with the strongest
evidence of enrichment. The International Schizophrenia
Consortium has used similar multiple-threshold approaches
when analysing GWAS data to determine the amount of
Table 1. Description of the samples.
Phenotype Sample Cases Controls Cases/controls in PGC* Genotyping platform
Healthy NCNG 670 Illumina Human610-Quad
BPD Norwegian-TOP 575 417 203/349 Affymetrix Genome-Wide Human SNP Array 6.0
German 682 1300 675/1297 Illumina HumanHap550v3
WTCCC 1868 2938 1571/2931 Affymetrix GC500K
PGC 7481 9250 Several (see ref. 19)
SCZ Norwegian-TOP 405 417 248/351 Affymetrix Genome-Wide Human SNP Array 6.0
German-Dutch 1169 3714 1178/1935 Illumina HumanHap550v3
Danish 573 453 482/457 Illumina Human610-Quad
PGC 9394 12462 Several (see ref. 48)
BPD, bipolar disorder; SCZ, schizophrenia; NCNG, Norwegian Cognitive NeuroGenetics; TOP, Norwegian Thematically Organized Psychosis; WTCCC, British Wellcome
Trust Case Control Consortium; Danish, Danish sub-sample of the Scandinavian Collaboration on Psychiatric Etiology; PGC, Psychiatric Genomics Consortium.
*indicates the cases and controls in the single-centre samples that are also included in the PGC multi-centre sample.
doi:10.1371/journal.pone.0081052.t001
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variance that can be explained by including variants of lower
effect size [56].
Gene Set Enrichment Analyses. The Gene Set Enrichment
Analysis (GSEA) method has been developed and extensively used
for global gene expression studies, but is increasingly being used in
the analysis of GWAS [54,57–59]. It assesses whether a predefined
gene set shows significant enrichment of signal (or association in
GWAS) in a ranked list of genes, i.e. if the selected set clusters at
the top of the ranked lists or is randomly distributed throughout
the list. Here we used GSEA to test the cognitive trait-associated
gene sets for enrichment of association in the ranked genes from
GWASs of psychiatric disorders (Figure 1).
GSEA calculates an enrichment score (ES) that increases when
a gene from the (neurocognitive) gene set is identified among the
ranked list of genes emerging from the (psychiatric) GWAS and
decreases when it is not. Specifically, we used a weighted (p = 1)
ES, which weights the genes within the gene set by the strength of
their association with the phenotype and thus assigns a higher ES
to gene sets clustering higher up in the ranked list as opposed to
those clustering in the middle of the ranked list. The significance,
or p-value, of the ES is determined by permuting (1000 times) the
ranked list and recalculating the ES to create a null distribution to
which the ES of the candidate gene set is compared. Each GSEA
was performed three times in order to ensure the reproducibility of
the permutation-based p-values. In addition, GSEA produces a
normalized ES (NES), which is based on the ESs for all dataset
permutations and enables comparison of NESs across gene sets.
Here, all 99 cognitive trait-associated gene sets were tested
together using the gene matrix file format option in GSEA in order
to utilize and retain the false discovery rate (FDR) q-value. The
FDR is an estimate of the proportion of significant results (at
p#0.05) that are false positives and has become widely accepted as
a powerful multiple-testing correction approach in GWAS [60]. As
implemented in GSEA, the FDR q-value adjusts both for the
multiple (i.e. 99) gene sets tested simultaneously and for the gene
set size [61]. The average FDR q-value of the three runs is
reported, together with the corresponding p-values. Gene sets with
a p-value#0.05 and an FDR q-value#0.25 were declared
nominally significantly enriched and taken forward for subsequent
validation, as described below.
We performed additional validation tests in order to evaluate
the robustness of our findings. Detailed methods are presented in
the Supporting Information. Notably, we used a random sets
approach to validate the findings. For each of the nominally
enriched sets (i.e. p-value#0.05 and FDR q-value#0.25), we
generated 100 random gene sets that mimicked the candidate gene
sets with respect to the number of genes in the set, the number of
SNPs within each gene, and the total number of sets tested
Figure 1. Schematic representation of the overall method. A1–A5: GWAS were performed for nine cognitive traits selected from the battery
phenotyped in the healthy Norwegian NCNG sample (A1). Using the LDsnpR algorithm [51], SNPs were assigned to gene bins (A2–3) and the gene
bins were scored using the minimum p-value corrected for the number of SNPs in the bin with an adjusted Sidak p-value. The gene scores were
ranked (smallest Sidak p-value to biggest – A4). These GWAS-based ranked lists of genes were used to generate the candidate gene sets, which
comprised the top 25, 50, 100, 250, 500, 750, 1000, 1250, 1500, 1750 and 2000 genes associated with each of the cognitive traits (A5). Thus, the
candidate gene sets were overlapping, and there was an incremental increase in the number of genes per set. B1–B4: The GWAS data for the
psychiatric disorders (B1) were subjected to the same pipeline for assigning SNPs to gene bins (B2–3), scoring (see manuscript), and ranking the
genes by their score (smallest Sidak p-value to the biggest – B4).
doi:10.1371/journal.pone.0081052.g001
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together. These 100 mimic sets were run together with the
candidate sets in other to determine whether the enrichment was
higher in the candidate sets than the random sets. Candidate gene
sets which scored an NES higher than 98% of the random sets was
declared statistically significantly enriched.
Results
From the battery of cognitive tests used to phenotype a sample
of 670 healthy Norwegians [27], we selected 9 cognitive traits
relevant to SCZ and BPD. General cognition/intelligence was
assessed by the ‘‘Estimated IQ’’, the ‘‘Matrix Reasoning’’ and the
‘‘Verbal Abilities’’ from the Wechsler abbreviated scale of
intelligence [35]; verbal memory by ‘‘Learning’’ and ‘‘Delayed
Verbal Memory’’ from the California Verbal Learning Test [37];
executive function by the 3rd condition (‘‘Colour-word interfer-
ence) of the Delis-Kaplan Executive function system colour-word
interference test and visuospatial attention by three reaction times
obtained during the Cued Discrimination Task (the valid, invalid
and neutral conditions [38], ‘‘Visuospatial attention 1/2/3’’).
Further details on the full battery of tests carried out on the
NCNG sample are given in Table S1 in File S1 and in Espeseth et
al. [27]. The correlations between the selected traits at the
phenotypic and gene levels are given in Tables S2 and S3 in File
S1, respectively. For each of the 9 traits, we performed a gene-
based analysis of the GWAS, constructing candidate gene sets
comprising the most associated genes. These gene sets were then
tested for enrichment of association in previously published,
independent GWASs of SCZ [42–44] and BPD [45–47]. The
workflow is shown in Figure 1.
The enrichment of association was tested using Gene Set
Enrichment Analysis (GSEA). The multiple-testing correction
FDR q-value was used to correct for gene set size and the number
of gene sets tested (see the Supporting Information for explanation
of the different values). In expression studies, a nominal threshold
of significance (p-value#0.05) and an FDR q-value#0.25) is
recommended [61]. For GWAS, an optimal FDR threshold has
not yet been established. Thus, an FDR q-value#0.25 was
retained as an initial threshold in order to select gene sets for
further validation. Detailed methods are presented in the
Supporting Information. Furthermore, the q-value corrects for
the number of genes sets tested (99 in this study) based on the
assumption that these sets are independent. In this study, however,
the sets are not independent since the 11 sets generated for each
trait are nested and the traits themselves are correlated (Table S3
in File S1). Thus the FDR q-value correction may be considered
conservative.
In particular, for each of the enriched sets (i.e. q-value!0.25
and p-value!0.05) in each of the psychiatric disorder samples
tested, we generated 100 random gene sets that mimicked the
candidate gene sets with respect to the number of genes in the set,
the number of SNPs within each gene, and the total number of sets
tested together. Candidate gene sets which showed stronger
evidence of enrichment, as determined by the NES, than greater
than 98% of the random gene sets were considered validated.
(measured by the normalized enrichment score, see Supporting
Information).
As a means of further validation, we repeated the gene set-based
analyses using a set of housekeeping genes (Table S5 in File S1),
and we also tested the cognitive gene sets against the WTCCC
non-psychiatric datasets in order to demonstrate specificity to
psychiatric phenotypes. The lowest q-value obtained was 0.21, for
Type 2 Diabetes (Table S6 in File S1). The final validation test,
which involved pruning genes that were in high LD with other
genes in the list, was designed to ensure that the observed
enrichment of the neurocognitive gene sets in the SCZ datasets is
not entirely due to LD between genes (Table S7 in File S1).
For BPD, the most significantly enriched gene set was the
visuospatial attention.1 225 set in the German sample. Another
visuospatial attention set (visuospatial attention.2 225) also
showed enrichment in the German sample and a trend towards
enrichment in the WTCCC sample. The difference between these
two tests is that the valid condition is analyzed in visuospatial
attention.1 while the invalid condition is analyzed in visuospatial
attention.2 [38]. At the cognitive level, these are two different tests,
even though they are highly correlated (0.97, Table S2 in File S1);
at the gene level the correlation was smaller (0.50, Table S3 in File
S1). In addition, several of the sets for verbal abilities in the
German sample (225, 250, and 2100) and in the WTCCC
samples (225) met our pre-defined criteria for enrichment and
were validated; the delayed verbal memory-25 set also showed
enrichment in the German sample (see Table 2 for the p- and q-
values and Table S4 in File S1 for the mimic set test results). None
of these sets showed significant enrichment in either the smaller
TOP sample or the PGC sample, but, notably, sets for verbal
abilities, visuospatial attention and delayed verbal memory had the
lowest FDR q-values in these samples.
Again using the same criteria to define enriched sets, we
observed that for SCZ, the colour-word interference 225 gene set
was enriched both in the German-Dutch sample and in the Danish
sample (see Table 3 for the p- and q-values and Table S4 in File S1
for the mimic set test results). The colour interference 250 set also
showed significant enrichment in the Danish sample, but the
enrichment was borderline in the German-Dutch sample. The
learning 2250 set was enriched in the PGC sample. The q-value
can be sensitive to sample-specific factors, like the size of the
sample, which may be relevant to smaller samples like the
Norwegian TOP sample, or the heterogeneity of the sample,
which is most likely to be relevant to multi-centre samples such as
the PGC samples. While only one gene set met our criteria for
significant enrichment and subsequent validation in the PGC, the
five most enriched sets are provided. Interestingly, although the
colour interference 225 set did not surpass the significance
threshold in the Norwegian-TOP and PGC samples, it was the 1st
and 2nd most strongly enriched set in these samples respectively.
The visuospatial sets also showed a trend for enrichment in these
two samples.
Interestingly, the enrichment signal in each of the SCZ and
BPD GWASs was driven by different genes within the colour-word
interference candidate set for SCZ (see Table S8 in File S1) and
within the verbal abilities, visuospatial attention and delayed
verbal memory sets for BPD (see Table S9 in File S1), attesting to
the heterogeneity and polygenicity of these traits, and to the utility
of such integrated approaches.
In addition, considering the hypothesis that SCZ and BPD
overlap at the genetic level, we looked for overlap of the most
strongly enriched cognitive gene sets in the PGC SCZ and BPD
samples, as they are the biggest samples tested (Table S10 in File
S1). Considering the enrichment rank, several gene sets for colour
interference, verbal abilities and visuospatial attention were among
the top 10 most enriched sets for both disorders, but no candidate
set was significantly enriched in both disorders (at q-value#0.25).
Discussion
In this study we identified candidate sets of genes associated
with cognitive abilities in healthy adults, and we screened these sets
for specific enrichment of association in SCZ or BPD. We chose to
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perform gene-based analysis as this method allows for more
flexibility in the comparison of genetic effects between traits than
single-marker methods. In particular, and in contrast to standard
single-marker analysis, gene-based analyses allow for allelic
heterogeneity [24,51,62]. The results of our study provide
evidence that cognitive abilities might be suitable phenotypes to
use for the identification of genetic factors overlapping with those
implicated in psychiatric disorders.
Gene sets associated with verbal abilities, visuospatial attention
and delayed verbal memory were the most enriched for association
in the BPD datasets. Neurocognitive dysfunctions are not as well
defined in BPD as they are in SCZ [28,63,64]. For SCZ, deficits in
executive function, verbal abilities (learning and memory),
attention and speed of processing [29–31] have been reported,
which corroborate our findings. It has been observed that the
cognitive functions impaired in SCZ are often also impaired in
BPD but to a lesser extent, and that cognitive dysfunction is
determined more by history of psychosis than by standard
diagnosis [32]. From this perspective, it would be interesting to
apply the approach we describe here to cross-disorder samples,
comprising patients who share common clinical symptoms, such as
psychosis for instance. In the extended PGC BPD sample, none of
the enrichments were significant, which might reflect a higher
clinical or genetic heterogeneity between and/or within samples
for BPD than for SCZ. In other genetic studies, it has often been
observed that the genetic signal is stronger for SCZ than for BPD
[65]. These problems could be overcome by analyzing even better
annotated BPD samples to gain power in more homogenous
samples. Further work is needed to establish whether particular
subgroups of BPD patients show greater impairment in neuro-
cognitive control and to determine whether the enrichment of
association of the different gene sets is more consistent in specific
subgroups.
For SCZ, gene sets associated with the colour-word interference
test show the greatest enrichment out of all the sets analyzed.
Cognitive neuroscience studies of SCZ are pointing towards
deficits in information-processing functions involved in cognitive
control or executive functions – the ability to regulate, coordinate,
and sequence thoughts and actions in accordance with internally
maintained behavioral goals [33,66]. Performance in colour-word
interference tests partly depends on cognitive inhibition, a set of
processes that play important roles in cognitive control. Deficits in
Table 2. Testing gene sets associated with normal neurocognitive variation for enrichment of association with bipolar disorder.
Sample German WTCCC Norwegian - TOP PGC
Cases/controls 682/1300 1868/2938 575/417 7481/9250
Gene sets R p-value q-value R p-value q-value R p-value q-value R p-value q-value
Visuospatial attention.1 225 1a 0.00* 0.0063 n.e. - - n.e. - - n.e. - -
Visuospatial attention.2 225 2a 0.0047 0.023 4b 0.14 0.27 n.e. - - n.e. - -
Verbal abilities 225 3a 0.0073 0.033 2a 0.0047 0.036 n.e. - - n.e. - -
Verbal abilities 250 4a 0.0063 0.073 n.e. - - n.e. - - 1b 0.02 0.42
Verbal abilities 2100 5a 0.0013 0.088 n.e. - - 1b 0.19 0.28 n.e. - -
Visuospatial attention.3 225 6 0.04 0.096 n.e. - - n.e. - - n.e. - -
Visuospatial attention.3 250 9 0.028 0.12 n.e. - - n.e. - - n.e. - -
Learning 2100 10 0.013 0.17 n.e. - - n.e. - - n.e. - -
Delayed verbal memory 2100 11 0.037 0.17 n.e. - - n.e. - - 2b 0.042 0.54
Verbal abilities 2250 12 0.0007 0.18 n.e. - - n.e. - - 5b 0.016 0.63
Learning 2250 13 0.002 0.21 n.e. - - n.e. - - n.e. - -
Verbal abilities 2500 14 0.00* 0.22 n.e. - - n.e. - - n.e. - -
Delayed verbal memory 250 n.e. - - 3b 0.063 0.26 n.e. - - n.e. - -
Delayed verbal memory 225 n.e. - - 1a 0.0037 0.028 n.e. - - n.e. - -
Colour-word interference 225 n.e. - - n.e. - - n.e. - - 4b 0.23 0.62
Matrix reasoning 2100 n.e. - - n.e. - - 5b 0.22 0.29 n.e. - -
Delayed verbal memory 21000 n.e. - - 5b 0.041 0.29 4b 0.0073 0.29 n.e. - -
Visuospatial attention.1 22000 n.e. - - n.e. - - 2b 0.00033 0.28 n.e. - -
Colour-word interference 250 n.e. - - n.e. - - n.e. - - 3b 0.095 0.58
Visuospatial attention.1 2500 n.e. - - n.e. - - 3b 0.033 0.29 n.e. - -
For each GWAS dataset, the 5 most enriched candidate sets are shown. For the German dataset, the 14 most enriched sets are presented to show the overlap with the
other datasets. The rank position (R) of the gene set within the total number of gene sets tested is determined by the average false discovery rate (q-value, obtained
from 3 GSEA runs with 1,000 permutations each). The maximum standard deviation from the average q-value was 0.07. Sets that passed the enrichment threshold (p-
value#0.05, FDR q-value#0.25) were tested for validation using random mimic sets (see Table S4 in File S1).
‘‘a’’indicates sets that were more enriched than 98% of the random sets (i.e. validated sets).
‘‘b’’indicates sets that did not pass the enrichment threshold but were among the 5 most enriched in the corresponding sample.
Sets that did not pass the enrichment threshold and ranked outside the top 5 are indicated by ‘‘n.e.’’. Visuospatial attention.1 – Visuospatial attention task with valid cue
to the location of the visual target; Visuospatial attention.3 – Visuospatial attention task with neutral cue to the location of the visual target. The number after each gene
set name represents the number of genes within that set (e.g. the Colour-word interference 225 set contains the top 25 genes within the colour-word interference
ranking list of genes).
*A reported p-value of zero (0.0) indicates an actual p-value of less than 1/number-of-permutations.
doi:10.1371/journal.pone.0081052.t002
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neurocognitive tests of cognitive control are observed in patients with
SCZ. Specifically in the colour-word interference test, patients with
SCZ tend to use more time in the interference condition than
controls, indicating impaired cognitive inhibition [67]. Such cognitive
inhibition, a subdomain of cognitive control that is especially engaged
during the colour-word interference test, involves ‘‘top-down’’
regulation from the prefrontal cortex areas to subcortical areas,
especially from the dorsolateral prefrontal and the anterior cingulate
cortices, which have also been recurrently implicated in SCZ [68,69].
At the genetic level, it has been shown that individual loci implicated
in SCZ can also influence cognitive control. For example the variant
rs1344706 in the ZNF804A gene, which is well characterized for its
effect in SCZ [70], is associated with variability in activation of
prefrontal cortex areas during a cognitive control task [71]. Here,
using a gene-based polygenic approach and several large, indepen-
dent samples, we provide evidence of an overlap between the group
of genes that influence colour-word interference in healthy adults and
genes associated with SCZ.
The learning 2250 gene set was the most significantly enriched
in the large PGC SCZ GWAS, and the learning 2500 set was
enriched in the Danish sample. These sets contained genes that are
associated with the learning slope during a memory test (the
California Verbal Learning Test, [36]). Impairments in memory in
general have been reported in patients with SCZ, though these
impairments have been observed for both episodic and working
memory [34]. Here the delayed verbal memory sets did not show
enrichment in the samples that were tested, but this could be due to
a lack of power. Despite this negative result, it is interesting to note
that a genetic approach can be used to dissect the overlap between
cognitive functions and SCZ.
While our results require replication, further validation and
extension to other cognitive traits and other psychiatric disorders,
it is encouraging to observe that genetic studies using polygenic
and pleiotropic models are converging with other approaches in
implicating specific cognitive functions in psychiatric disorders.
Additional gene set-based studies might help to elucidate and
dissect the relationship between cognitive functions and dysfunc-
tions. Several cognitive functions implicated by our study will need
further investigation, especially the functions recruited during the
colour interference test, which has not gained as much support as a
potential endophenotype for SCZ as other traits. We also highlight
the need for samples with higher levels of phenotypic character-
ization in order to better deconstruct the effect of cognitive
impairments in psychiatric disorders at the genetic level.
Supporting Information
File S1 This file contains ten supporting tables (S1–S10) and
supporting methods.
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